Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SK bioscience, a South Korean pharmaceutical firm, announced on Thursday, March 21, that it has exported its influenza vaccine to Thailand. The company developed a cell-cultured influenza vaccine, and after securing the required approvals and permits, it started exporting its Sky Cellflu to the country.
First Batch of Deliveries
According to The Korea Herald, SK Bioscience has already completed the first delivery, which consists of 440,000 doses of the Sky Cellflu vaccine. The products were handed over to its local partner, Biogenetech.
The Korean pharmaceutical company expects to receive more orders and expand its sales once the new influenza vaccine is distributed in Thailand. The deal also marks SK Bioscience's expansion in the Southeast Asian market and entry into the Southern space.
Timely Arrival of the Flu Vaccines
Korea IT Times reported that Thailand has been affected by flu strains, and vaccination is being sought to prevent infections. SK bioscience's Sky Cellflu was also approved by the World Health Organization (WHO) for use in the country.
Moreover, this export is expected to become an excellent example of proper vaccination to combat influenza. Meanwhile, Sky Cellflu already secured proper licenses for distribution in 12 countries, including Malaysia, Thailand, Chile, Singapore, Mongolia, and Pakistan.
World's First Cell Culture-Based Flu Vaccine
SK bioscience's SKYCellflu is said to be the first cell culture-based influenza vaccine in the world. It obtained WHO Pre-qualification (PQ) certification for safe usage and dissemination worldwide.
"The export of SKYCellflu to Thailand serves as a stepping-stone for entering the Southeast Asian and Southern Hemisphere markets and expanding into the global market," SK bioscience's chief executive officer, Ahn Jae Yong, said in a press release. "In addition to diversifying our existing product markets, we are committed to developing vaccines with blockbuster potential, such as our next-generation pneumococcal conjugate vaccine candidate, which is expected to enter phase III clinical trials this year."
Photo by: SK Bioscience Press Release
